Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q2 2023 Earnings Conference Call August 7, 2023 4:30 PM ET

Company Participants

Neda Safarzadeh - VP, Head IR, Public Relations and Marketing

Joseph Payne - President and CEO

Andy Sassine - CFO

Pad Chivukula - CSO and COO

Conference Call Participants

Yasmeen Rahimi - Piper Sandler

Myles Minter - William Blair

Evan Wang - Guggenheim Securities

Pete Stavropoulos - Cantor Fitzgerald

Yanan Zhu - Wells Fargo

Carly Kenselaar - Citi

Thomas Yip - H.C. Wainwright

Yale Jen - Laidlaw and Company

Operator

Greetings, and welcome to Arcturus Therapeutics Second Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host Neda Safarzadeh, Vice President, Head of Investor Relations, Public Relations, and Marketing. Please go ahead.

Neda Safarzadeh

Thank you. operator. Good afternoon, and welcome to Arcturus Therapeutics Second Quarter 2023 Financial Update and Pipeline Progress Call.

Today's call will be led by Joseph Payne, our President and CEO; and Andy Sassine, our CFO. Dr. Pad Chivukula, our CSO and COO will join them for the Q&A session.

Before we begin, I would like to remind everyone that the statements made during this call regarding matters that are not historical facts are forward-looking statements within the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties, and assumptions that may cause actual results, performance, and achievements to differ materially from those expressed or implied by the statements. Please see the forward-looking statement disclaimer on the company's press release issued earlier today, as well as the risk factors section in our most recent Form 10-K and in subsequent filings with the SEC.

In addition, any forward-looking statements represent our view only as of the date such statements are made. Arcturus specifically disclaims any obligation to update such statements to reflect further information, events, or circumstances.

And with that, I will now turn the call over to Joe.

Joseph Payne

Thank you, Neda. It's good to be with you again, everybody. We look forward to providing our updates today on our quarterly investor call.

I will begin my remarks by highlighting our progress with our ARCT-154 COVID-19 vaccine Phase 3 program. We're pleased with the rapid development and regulatory process -- progress recently made with our alliance partner Meiji Pharma toward the approval of ARCT-154 by the Japanese regulatory authorities. The ARCT-154 submission is supported by an active-controlled Phase 3 booster vaccine study that was executed during a period when multiple COVID variants were circulating.